GO:1903620 positive regulation of transdifferentiation: Cellular Reprogramming Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903620 (positive regulation of transdifferentiation) describes any biological process that activates or increases the frequency, rate or extent of transdifferentiation, the direct conversion of one differentiated cell type into another [1, 6].
• Key drivers include transcription factors such as GATA4, LHX2, CREB1, and signaling mediators like cAMP, JNK, and protein kinase C isoforms [2, 3, 6, 7].
• Transdifferentiation is central to tissue repair, fibrosis, cancer progression, and metabolic disease, making its positive regulation a high-value therapeutic target [2, 4, 5, 8].
• Experimental models range from genetic knockout and point-mutation knock-in in mice to human induced neuron conversion and multi-omics profiling of living human islets [5, 6, 8].
• CRISPR-based knockout, knock-in, overexpression, and library screening enable causal dissection of positive regulators of transdifferentiation [1, 3, 4].
• Understanding this GO term supports development of regenerative therapies, antifibrotic strategies, and cancer differentiation treatments [2, 4, 7].
Description
Transdifferentiation is the direct conversion of one differentiated cell type into another without passing through a pluripotent intermediate. The Gene Ontology term GO:1903620, positive regulation of transdifferentiation, captures any process that activates or increases the frequency, rate or extent of this conversion. This term is critical for researchers because transdifferentiation underlies normal tissue repair, pathological fibrosis, cancer cell plasticity, and emerging regenerative medicine strategies [1, 2, 6]. For example, endothelial GATA4 prevents a pathogenic switch in angiocrine signaling that drives liver fibrosis and regeneration, directly linking positive regulation of transdifferentiation to organ repair. Similarly, forskolin-driven conversion of human somatic cells into induced neurons through the cAMP-CREB1-JNK signaling axis demonstrates that pharmacological activation of this process can generate neurons for disease modeling and therapy. In cancer, cancer-associated endocrine cells participate in pancreatic carcinogenesis, and LHX2 rewires the metabolic and epigenetic landscape to drive prostate cancer progression, highlighting how positive regulators of transdifferentiation can be hijacked in malignancy [1, 3]. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of GO:1903620, its molecular players, disease relevance, and experimental methods.
positive regulation of transdifferentiation At A Glance
| GO ID | GO:1903620 |
|---|---|
| GO term | positive regulation of transdifferentiation |
| Ontology | biological_process |
| Synonym | activation of transdifferentiation; up regulation of transdifferentiation; up-regulation of transdifferentiation; upregulation of transdifferentiation |
| Definition | Any process that activates or increases the frequency, rate or extent of transdifferentiation. |
| Major function | Promotes direct cell fate conversion between differentiated cell types |
| Related processes | Cell fate commitment, epithelial-mesenchymal transition, fibrosis, regeneration, cancer plasticity |
| Key regulators | GATA4, LHX2, CREB1, JNK, protein kinase C isoforms, CCN2 |
| Research relevance | Regenerative medicine, antifibrotic therapy, cancer differentiation therapy, metabolic disease |
What Is GO:1903620?
According to the QuickGO definition, GO:1903620 (positive regulation of transdifferentiation) refers to any process that activates or increases the frequency, rate or extent of transdifferentiation. In other words, it encompasses molecular signals, transcription factors, epigenetic modifiers, and environmental cues that promote the direct conversion of one differentiated cell type into another. This term is a biological process and includes synonyms such as activation of transdifferentiation, up regulation of transdifferentiation, up-regulation of transdifferentiation, and upregulation of transdifferentiation.
Why Is positive regulation of transdifferentiation Important in Cell Biology?
Positive regulation of transdifferentiation is important because it governs tissue plasticity in health and disease. It enables repair processes such as endothelial-to-mesenchymal transition in liver fibrosis and regeneration, and it drives pathological conversions in atherosclerosis and chronic obstructive pulmonary disease [2, 4, 8]. In cancer, transdifferentiation programs contribute to tumor heterogeneity and progression, as seen in pancreatic carcinogenesis and prostate cancer [1, 3]. Understanding how to activate or inhibit this process offers therapeutic opportunities for fibrosis, neurodegeneration, diabetes, and cancer.
• Controls direct cell fate conversion without pluripotent intermediates, enabling regenerative therapies.
• Endothelial GATA4 prevents a pathogenic switch in angiocrine signaling, linking positive regulation of transdifferentiation to liver fibrosis and regeneration.
• CCN2 regulates smooth muscle cell transdifferentiation and lipid accumulation in atherosclerosis, making it a target for cardiovascular disease.
• Impaired AT2 to AT1 cell transition in PM2.5-induced COPD highlights the role of transdifferentiation in lung disease.
• Forskolin-driven conversion of human somatic cells into induced neurons through cAMP-CREB1-JNK signaling offers a route to neuronal replacement.
• Protein kinase C isoforms distinctly regulate cardiac fibroblast proliferation and transdifferentiation, with implications for antifibrotic therapies.
• Cancer-associated endocrine cells participate in pancreatic carcinogenesis, linking transdifferentiation to tumor initiation.
• LHX2 rewires the metabolic and epigenetic landscape to drive prostate cancer progression, showing how positive regulators can be oncogenic.
• Multi-omics profiling of living human pancreatic islet donors reveals heterogeneous beta cell trajectories towards type 2 diabetes, implicating transdifferentiation in metabolic disease.
• CRISPR screening and bioinformatics can identify novel positive regulators of transdifferentiation for therapeutic targeting [1, 3, 4].
What Happens During positive regulation of transdifferentiation?
Initiation by extracellular and intracellular signals
In simple terms: A cell receives a signal that tells it to change its identity.
Positive regulation of transdifferentiation begins when extracellular cues such as forskolin, which elevates cAMP, or intracellular signaling cascades like JNK are activated. Forskolin-driven conversion of human somatic cells into induced neurons requires regulation of the cAMP-CREB1-JNK signaling axis. Similarly, classical and novel protein kinase C isoforms distinctly regulate cardiac fibroblast proliferation and transdifferentiation, indicating that specific signaling inputs can initiate the conversion process.
Transcriptional rewiring by pioneer factors
In simple terms: Master transcription factors switch on genes that define the new cell type.
Once initiated, transcription factors such as GATA4, LHX2, and CREB1 orchestrate transcriptional rewiring. Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling. LHX2 rewires the metabolic and epigenetic landscape to drive tumor progression in prostate cancer, demonstrating how a single factor can promote transdifferentiation-associated programs. CREB1 is a downstream effector of cAMP signaling in the conversion of somatic cells into neurons.
Epigenetic and metabolic remodeling
In simple terms: The cell changes which genes are accessible and how it uses energy.
Transdifferentiation requires epigenetic and metabolic remodeling to stabilize the new cell identity. LHX2 rewires the metabolic and epigenetic landscape to drive prostate cancer progression, indicating that positive regulation involves changes in chromatin accessibility and metabolism. Multi-omics profiling of living human pancreatic islet donors reveals heterogeneous beta cell trajectories towards type 2 diabetes, reflecting metabolic and epigenetic shifts during cell fate changes.
Cytoskeletal and morphological changes
In simple terms: The cell changes its shape and internal structure to match the new cell type.
As transdifferentiation proceeds, cells undergo morphological and cytoskeletal reorganization. CCN2 regulates smooth muscle cell transdifferentiation and lipid accumulation in atherosclerosis, a process that involves changes in cell structure and function. Impaired AT2 to AT1 cell transition in PM2.5-induced COPD reflects failed morphological and functional conversion of alveolar epithelial cells.
Stabilization and maintenance of the new identity
In simple terms: The new cell type becomes stable and keeps its new job.
Positive regulation of transdifferentiation culminates in the stabilization of the new cell identity. Cancer-associated endocrine cells participate in pancreatic carcinogenesis, suggesting that once transdifferentiated, these cells maintain a stable phenotype that contributes to tumor progression. Endothelial GATA4 prevents a pathogenic switch in angiocrine signaling, indicating that sustained expression of key regulators is required to maintain the transdifferentiated state.
Key Genes Involved in GO:1903620 positive regulation of transdifferentiation
The following genes and proteins have been experimentally implicated in positive regulation of transdifferentiation, as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GATA4 | Transcription factor controlling endothelial angiocrine signaling | Prevents pathogenic switch in liver fibrosis and regeneration |
| LHX2 | Transcription factor rewiring metabolic and epigenetic landscape | Drives prostate cancer progression |
| CREB1 | Transcription factor downstream of cAMP signaling | Mediates forskolin-driven conversion of somatic cells into neurons |
| JNK | Stress-activated protein kinase | Required for cAMP-CREB1-JNK signaling in induced neuron conversion |
| CCN2 | Cellular communication network factor 2 | Regulates smooth muscle cell transdifferentiation and lipid accumulation in atherosclerosis |
| PRKCA | Classical protein kinase C isoform | Regulates cardiac fibroblast proliferation and transdifferentiation |
| PRKCE | Novel protein kinase C isoform | Distinctly regulates cardiac fibroblast transdifferentiation |
| AT2 cell markers | Alveolar type 2 epithelial cell identity | Impaired AT2 to AT1 transition in COPD model |
| AT1 cell markers | Alveolar type 1 epithelial cell identity | Target of impaired transition in PM2.5-induced COPD |
| Cancer-associated endocrine cells | Endocrine-like cells in pancreatic tumors | Participate in pancreatic carcinogenesis |
| Beta cell markers | Pancreatic islet beta cell identity | Heterogeneous trajectories towards type 2 diabetes |
| Endothelial markers | Liver endothelial cell identity | GATA4 controls angiocrine signaling in fibrosis |
| Smooth muscle cell markers | Vascular smooth muscle cell identity | CCN2 regulates transdifferentiation in atherosclerosis |
| Cardiac fibroblast markers | Fibroblast identity in heart | PKC isoforms regulate proliferation and transdifferentiation |
| Neuronal markers | Induced neuron identity | Forskolin-driven conversion via cAMP-CREB1-JNK |
| Prostate cancer markers | Tumor progression markers | LHX2 drives metabolic and epigenetic rewiring |
| Pancreatic islet markers | Islet cell identity | Multi-omics profiling reveals beta cell trajectories |
How Is positive regulation of transdifferentiation Regulated?
Positive regulation of transdifferentiation is controlled by multiple signaling pathways and transcription factors. The cAMP-CREB1-JNK signaling axis is essential for forskolin-driven conversion of human somatic cells into induced neurons. Classical and novel protein kinase C isoforms distinctly regulate cardiac fibroblast proliferation and transdifferentiation, indicating isoform-specific control. Endothelial GATA4 acts as a key regulator that prevents a pathogenic switch in angiocrine signaling, thereby controlling liver fibrosis and regeneration. LHX2 rewires the metabolic and epigenetic landscape to drive prostate cancer progression, showing that oncogenic signals can hijack this process. CCN2 regulates smooth muscle cell transdifferentiation and lipid accumulation in atherosclerosis, providing another layer of regulation. These examples illustrate that positive regulation of transdifferentiation is context-dependent and tightly controlled by extracellular signals, kinases, and transcription factors.
positive regulation of transdifferentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GATA4 | Liver fibrosis and regeneration | Endothelial-specific knockout mouse |
| LHX2 | Prostate cancer progression | Prostate cancer xenograft with LHX2 overexpression |
| CCN2 | Atherosclerosis | Smooth muscle cell-specific knockout mouse |
| CREB1 | Neurodegeneration | Human somatic cell conversion to induced neurons |
| AT2/AT1 markers | Chronic obstructive pulmonary disease | PM2.5-induced mouse model |
Cancer progression and metastasis
Positive regulation of transdifferentiation contributes to cancer progression. Cancer-associated endocrine cells participate in pancreatic carcinogenesis, suggesting that transdifferentiation of endocrine-like cells promotes tumor initiation. LHX2 rewires the metabolic and epigenetic landscape to drive tumor progression in prostate cancer, demonstrating that positive regulators can be oncogenic drivers. Targeting these transdifferentiation programs may offer new therapeutic avenues.
Liver fibrosis and regeneration
Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling. This indicates that positive regulation of transdifferentiation in endothelial cells can be either protective or pathogenic depending on context. Modulating GATA4 activity may promote regeneration while limiting fibrosis.
Cardiovascular disease and atherosclerosis
CCN2 regulates smooth muscle cell transdifferentiation and lipid accumulation in atherosclerosis, linking positive regulation of transdifferentiation to plaque formation. Protein kinase C isoforms distinctly regulate cardiac fibroblast proliferation and transdifferentiation, with implications for antifibrotic therapies. These findings highlight the cardiovascular relevance of this GO term.
Metabolic and respiratory disease
Multi-omics profiling of living human pancreatic islet donors reveals heterogeneous beta cell trajectories towards type 2 diabetes, implicating transdifferentiation in metabolic disease. Impaired AT2 to AT1 cell transition in PM2.5-induced COPD demonstrates that failed transdifferentiation contributes to respiratory disease. Forskolin-driven conversion of human somatic cells into induced neurons offers a potential strategy for neurodegenerative conditions.
From positive regulation of transdifferentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GATA4 prevent pathogenic endothelial transdifferentiation in liver fibrosis? | Endothelial-specific GATA4 knockout mouse |
| Does LHX2 drive prostate cancer progression via metabolic rewiring? | LHX2 overexpression and knockout in prostate cancer cell lines |
| Does CCN2 regulate smooth muscle cell transdifferentiation in atherosclerosis? | CCN2 knockout and overexpression in smooth muscle cells |
| Can forskolin convert human somatic cells into neurons? | Human induced neuron conversion with cAMP-CREB1-JNK modulation |
| Do PKC isoforms differentially regulate cardiac fibroblast transdifferentiation? | PKC isoform-specific knockout or overexpression in cardiac fibroblasts |
| Is AT2 to AT1 transition impaired in COPD? | PM2.5-induced mouse model of COPD |
How to Study the positive regulation of transdifferentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify transdifferentiation signatures |
| Single-cell RNA-seq | Cell-to-cell heterogeneity | Map beta cell trajectories in diabetes |
| ATAC-seq | Chromatin accessibility | Detect epigenetic rewiring by LHX2 |
| ChIP-seq | Transcription factor binding sites | Map GATA4 or CREB1 targets [2, 6] |
| Metabolomics | Metabolic flux and metabolite levels | Uncover metabolic rewiring in cancer |
| CRISPR knockout | Loss-of-function phenotypes | Test causal role of GATA4 in fibrosis |
| CRISPR knock-in | Tagged or mutant protein expression | Study point mutations in PKC isoforms |
| Lineage tracing | Cell fate conversion in vivo | Track AT2 to AT1 transition in COPD |
Transcriptomic profiling
RNA sequencing and single-cell RNA sequencing can identify gene expression changes during positive regulation of transdifferentiation. Multi-omics profiling of living human pancreatic islet donors reveals heterogeneous beta cell trajectories towards type 2 diabetes, demonstrating the power of transcriptomics in this context.
Epigenetic and metabolic assays
ATAC-seq, ChIP-seq, and metabolomics can reveal epigenetic and metabolic rewiring. LHX2 rewires the metabolic and epigenetic landscape to drive prostate cancer progression, and these methods can uncover similar mechanisms in other systems.
Functional perturbation with CRISPR
CRISPR knockout, knock-in, and overexpression enable causal testing of candidate regulators. For example, endothelial GATA4 knockout in mice demonstrated its role in liver fibrosis and regeneration, and CCN2 perturbation in smooth muscle cells linked it to atherosclerosis.
Imaging and lineage tracing
Live-cell imaging and lineage tracing can visualize transdifferentiation events. Impaired AT2 to AT1 cell transition in PM2.5-induced COPD was demonstrated using such approaches. Forskolin-driven conversion of human somatic cells into induced neurons can be monitored by neuronal marker expression.
How CRISPR Can Be Used to Study GO:1903620 positive regulation of transdifferentiation
Knockout
CRISPR knockout is used to delete positive regulators of transdifferentiation and assess loss-of-function phenotypes. Endothelial-specific GATA4 knockout in mice revealed its role in preventing a pathogenic switch in angiocrine signaling during liver fibrosis and regeneration. Similarly, CCN2 knockout in smooth muscle cells can test its requirement for transdifferentiation and lipid accumulation in atherosclerosis.
Point Mutation
CRISPR point mutation knock-in introduces specific amino acid changes to dissect domain functions. For example, mutating phosphorylation sites in CREB1 or JNK can test their role in forskolin-driven neuronal conversion. Point mutations in protein kinase C isoforms can reveal isoform-specific functions in cardiac fibroblast transdifferentiation.
Knock-in
CRISPR knock-in of reporter genes or epitope tags enables visualization and tracking of transdifferentiation. Tagging endogenous LHX2 with a fluorescent reporter allows monitoring of its expression during prostate cancer progression. Knock-in of lineage markers can trace AT2 to AT1 transition in COPD models.
Overexpression
CRISPR activation or cDNA overexpression can drive positive regulation of transdifferentiation. Overexpression of LHX2 in prostate cancer cells promotes tumor progression and metabolic rewiring. Forskolin-driven conversion of human somatic cells into induced neurons can be enhanced by overexpressing CREB1 or JNK pathway components.
How EDITGENE Supports positive regulation of transdifferentiation Research
Researchers studying positive regulation of transdifferentiation-related genes often need to determine whether a candidate gene is causally involved in cell fate conversion. EDITGENE provides comprehensive CRISPR gene editing services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of transdifferentiation research.
Frequently Asked Questions About positive regulation of transdifferentiation
What is GO:1903620 positive regulation of transdifferentiation?
GO:1903620 is a Gene Ontology biological process term defined as any process that activates or increases the frequency, rate or extent of transdifferentiation, the direct conversion of one differentiated cell type into another [1, 6].
What genes are involved in positive regulation of transdifferentiation?
Key genes include GATA4, LHX2, CREB1, JNK, CCN2, and protein kinase C isoforms, as demonstrated in liver fibrosis, prostate cancer, neuronal conversion, atherosclerosis, and cardiac fibroblast studies [2, 3, 4, 6, 7].
How is positive regulation of transdifferentiation studied?
Researchers use RNA-seq, single-cell RNA-seq, ATAC-seq, ChIP-seq, metabolomics, CRISPR knockout, knock-in, overexpression, and lineage tracing in models such as endothelial-specific knockout mice and human induced neuron conversion [2, 3, 5, 6, 8].
What diseases are linked to positive regulation of transdifferentiation?
It is linked to liver fibrosis, atherosclerosis, chronic obstructive pulmonary disease, type 2 diabetes, pancreatic carcinogenesis, and prostate cancer progression [1, 2, 3, 4, 5, 8].
What is the role of GATA4 in transdifferentiation?
Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling, thereby regulating positive regulation of transdifferentiation.
How does LHX2 drive prostate cancer progression?
LHX2 rewires the metabolic and epigenetic landscape to drive tumor progression in prostate cancer, acting as a positive regulator of transdifferentiation-associated programs.
Can forskolin induce transdifferentiation?
Yes, forskolin-driven conversion of human somatic cells into induced neurons occurs through regulation of the cAMP-CREB1-JNK signaling pathway.
What is the role of CCN2 in atherosclerosis?
CCN2 regulates smooth muscle cell transdifferentiation and lipid accumulation in atherosclerosis, contributing to plaque formation.
How do protein kinase C isoforms regulate transdifferentiation?
Classical and novel protein kinase C isoforms distinctly regulate cardiac fibroblast proliferation and transdifferentiation, with implications for antifibrotic therapies.
What is the link between transdifferentiation and COPD?
Impaired AT2 to AT1 cell transition in PM2.5-induced mouse model of chronic obstructive pulmonary disease demonstrates that failed transdifferentiation contributes to disease.
Conclusion
GO:1903620 positive regulation of transdifferentiation is a fundamental biological process that governs cell fate conversion in development, tissue repair, and disease. The verified literature highlights key regulators such as GATA4, LHX2, CREB1, JNK, CCN2, and protein kinase C isoforms, and links this process to liver fibrosis, atherosclerosis, COPD, diabetes, and cancer [1, 2, 3, 4, 5, 6, 7, 8]. Understanding these mechanisms offers opportunities for regenerative medicine, antifibrotic therapy, and cancer treatment. EDITGENE provides comprehensive CRISPR services to accelerate research in this field.
References
- 1. Chen Y et al.. 2024. Cancer-Associated Endocrine Cells Participate in Pancreatic Carcinogenesis.. Gastroenterology 167(6):1167-1182.e23 PMID: 39048054
- 2. Winkler M et al.. 2021. Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling.. J Hepatol 74(2):380-393 PMID: 32916216
- 3. Jiang J et al.. 2025. LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer.. Cancer Res 85(23):4751-4768 PMID: 40899980
- 4. Xu Q et al.. 2024. Cellular communication network factor 2 regulates smooth muscle cell transdifferentiation and lipid accumulation in atherosclerosis.. Cardiovasc Res 120(17):2191-2207 PMID: 39365752
- 5. Wigger L et al.. 2021. Multi-omics profiling of living human pancreatic islet donors reveals heterogeneous beta cell trajectories towards type 2 diabetes.. Nat Metab 3(7):1017-1031 PMID: 34183850
- 6. Wang G et al.. 2024. Forskolin-driven conversion of human somatic cells into induced neurons through regulation of the cAMP-CREB1-JNK signaling.. Theranostics 14(4):1701-1719 PMID: 38389831
- 7. Karhu ST et al.. 2021. Distinct Regulation of Cardiac Fibroblast Proliferation and Transdifferentiation by Classical and Novel Protein Kinase C Isoforms: Possible Implications for New Antifibrotic Therapies.. Mol Pharmacol 99(2):104-113 PMID: 33239332
- 8. Yu H et al.. 2022. Impaired AT2 to AT1 cell transition in PM2.5-induced mouse model of chronic obstructive pulmonary disease.. Respir Res 23(1):70 PMID: 35337337
